Pediatric pulmonology · 2025
Home Cough Monitoring Reveals Higher Nighttime Cough Burden in Children With Cystic Fibrosis Compared With Healthy Children.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Melzer Lilah D, Vigers Tim, Hanley Elinor T, Messinger Amanda, Hoppe Jordana E, Sagel Scott D, Zemanick Edith T
Аннотация
RATIONAL: Remote health-monitoring technologies such as cough monitors can track longitudinal changes in health status in children with cystic fibrosis (cwCF). We assessed the feasibility of a bedside cough monitor and hypothesized that cwCF would have a higher baseline cough frequency compared to healthy controls (HC), which would increase during pulmonary exacerbations (PEx).
METHODS: Cough monitors capturing continuous audio data during pre-set sleep times were provided for 3 months. Data were analyzed over 3 s intervals using a proprietary algorithm (CurieAi, Santa Clara, CA) to identify cough events. Multivariable modeling was used to compare baseline cough frequency (coughs per night) between cwCF and HC.
RESULTS: We enrolled 40 children (20 cwCF and 20 HC; median [range] age 11 years [2-18]) between February and August 2024. Most participants were White, 3 (7.5%) identified as Hispanic and/or Latino. CwCF were all treated with elexacaftor/tezacaftor/ivacaftor (ETI); baseline median (range) ppFEV1 was 107% (86%-124%). Data were captured over 82% of nights in the study period (median of 75.5 nights per participant, range 4-106). CwCF were more likely to cough at least once during the night compared to HC (IRR = 0.279, p = 0.02), and cough at a higher, albeit non-statistically significant rate (IRR = 1.805, p = 0.082). We could not determine whether cough frequency changed during PEx due to limited data collection surrounding reported PEx.
CONCLUSIONS: A passive cough monitor detected nighttime cough in cwCF and HC. CwCF with preserved lung function have more nights with cough than HC despite being on elexacator/tezacaftor/ivacaftor (ETI).
METHODS: Cough monitors capturing continuous audio data during pre-set sleep times were provided for 3 months. Data were analyzed over 3 s intervals using a proprietary algorithm (CurieAi, Santa Clara, CA) to identify cough events. Multivariable modeling was used to compare baseline cough frequency (coughs per night) between cwCF and HC.
RESULTS: We enrolled 40 children (20 cwCF and 20 HC; median [range] age 11 years [2-18]) between February and August 2024. Most participants were White, 3 (7.5%) identified as Hispanic and/or Latino. CwCF were all treated with elexacaftor/tezacaftor/ivacaftor (ETI); baseline median (range) ppFEV1 was 107% (86%-124%). Data were captured over 82% of nights in the study period (median of 75.5 nights per participant, range 4-106). CwCF were more likely to cough at least once during the night compared to HC (IRR = 0.279, p = 0.02), and cough at a higher, albeit non-statistically significant rate (IRR = 1.805, p = 0.082). We could not determine whether cough frequency changed during PEx due to limited data collection surrounding reported PEx.
CONCLUSIONS: A passive cough monitor detected nighttime cough in cwCF and HC. CwCF with preserved lung function have more nights with cough than HC despite being on elexacator/tezacaftor/ivacaftor (ETI).